News
Investors unfazed by FDA’s Covid vaccine framework
The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who are at high risk of becoming seriously ill. It will also require manufacturers to conduct clinical trials to show whether the vaccines benefit healthy younger adults and children.
Top health officials were aware of and actively took steps to “delay warning the public” for months in 2021 about the potential risks of patients suffering from heart-related ...
Zacks Investment Research on MSN2h
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 ShotsShares of prominent COVID-19 vaccine-makers Moderna MRNA, Pfizer PFE and BioNTech BNTX rose yesterday after the FDA issued new guidance for COVID-19 vaccine boosters. FDA’s New Requirements for ...
A former Pfizer scientist said the timing of the 2020 vaccine results “wasn’t a coincidence,” according to allegations ...
The House Judiciary Committee revealed Thursday that Pfizer’s former Global Head of Vaccines Research and Development, Dr.
The FDA plans to require new clinical trials for approval of annual COVID-19 boosters for healthy Americans under 65.
Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...
Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for ...
President Donald Trump’s administration is slated to lay out its approach to Covid vaccination at an event Tuesday that could ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback